Treats insomnia characterized. ANDA 76410, held by Teva. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 76410 (Zolpidem Tartrate), held by Teva, was first approved by FDA on Apr 23, 2007, with 11 approved supplements and 0 published complete response letters.
Zolpidem Tartrate Tablets USP are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem Tartrate Tablets USP have been shown to decrease sleep latency for up to 35 days in controlled clinical studies. The clinical trials performed in support of efficacy were 4 to 5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2007 | Original application | Approved |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Mar 8, 2023 | Supplement 28Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 29Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 19Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 23Labeling · Standard review | Approved | None posted |
| Nov 15, 2019 | Supplement 24Labeling · Standard review | Approved | None posted |
| Mar 19, 2015 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 4, 2013 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 8, 2010 | Supplement 8Labeling | Approved | None posted |
| Nov 6, 2008 | Supplement 4Labeling | Approved | None posted |
| Apr 23, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters